<rss version="2.0">
<channel>
<title>MindBranch: Healthcare</title>
<description>Healthcare market research products provide analysis of the latest trends, developments and market data for this industry.  Research information will help you make informed business decisions.</description>
<link>http://www.mindbranch.com/catalog/find.jsp?cat=heal</link>
<item>
<title>Freedonia Focus on Medical &amp; Dental Adhesives &amp; Sealants</title>
<link>http://www.mindbranch.com/products/R761-1074.html</link>
<description> <![CDATA[This report discusses US demand for medical and dental adhesives and sealants for the years 2003 and 2008, with forecasts for 2013.  Topics covered include market size, product and market segmentation, material research and product development, regulatory considerations, market environment, product and market forecasts, industry composition and leading participants.  Product segments covered are medical adhesives and sealants (including internal medical and external medical), and dental adhesives and sealants (including professional dental and denture adhesives and sealants).  Markets covered are primary care, dental office and consumer.  This 20 page report also includes a highlights summary and a resources ]]></description>
<pubDate>Mon, 30 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Freedonia Focus on Cancer Therapies</title>
<link>http://www.mindbranch.com/products/R761-1076.html</link>
<description> <![CDATA[This report discusses US demand for cancer therapies for the years 2003 and 2008, with forecasts for 2013.  Topics covered include market size, product and market segmentation, types of cancer, diagnosis and screening, technology and product development, market environment, product and market forecasts, industry composition and leading participants.  Product segments cover pharmaceuticals (biotechnology-based drugs and chemotherapy drugs) and services (surgery and radiation therapy); market segments include hospital, consumer/home healthcare, outpatient facility and other markets.  This 21 page report also includes a highlights summary and a resources ]]></description>
<pubDate>Mon, 30 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology Sector</title>
<link>http://www.mindbranch.com/products/R3470-3265.html</link>
<description> <![CDATA[The US biotechnology industry includes about 1,500 companies with combined annual revenue of about $70 billion. Major companies include Amgen, Biogen Idec, Genentech (owned by Switzerland-based Roche), Genzyme, Life Technologies, and Monsanto. Because many drugs are now developed using biotechnology, the biotechnology and pharmaceutical industries overlap considerably.  COMPETITIVE LANDSCAPE  Demand for biotechnology research in the fields of medicine, agriculture, food, and science is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise ]]></description>
<pubDate>Mon, 16 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Optometrists and Opticians</title>
<link>http://www.mindbranch.com/products/R3470-3278.html</link>
<description> <![CDATA[The retail optical industry in the US includes about 14,000 optician stores with combined annual revenue of $7 billion, and 16,000 offices of optometrists with combined annual revenue of $6 billion. Large opticians include Luxottica Retail (LensCrafters and Pearle Vision), Eye Care Centers of America, and US Vision. The optician segment of the market is fairly concentrated: the 50 largest chains hold about 60 percent of the market. The optometrist segment is highly fragmented.  Optometrists work mainly as solo practitioners or in small group practices. A typical group practice has less than $500,000 in annual revenue and four employees. About 1,000 practices have annual revenue over $1 million. Many optometrist practices include retail sales.   COMPETITIVE LANDSCAPE  Demand is driven by demographics, fashion, and changing healthcare practices. Most important is the aging US population, which is increasing demand for eye exams and glasses. The profitability of optometrist practices depends on efficient operations and ]]></description>
<pubDate>Mon, 16 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>United States Type 2 Diabetes Market</title>
<link>http://www.mindbranch.com/products/R3740-1.html</link>
<description> <![CDATA[Intellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market from 2009 -2013. This primary research report features information and analysis that can't be found anywhere else. Our report features information gathered from pharmaceutical, payer, and key opinion leader interviews. This report reveals what changes lay ahead for the diabetes market in the US. It evaluates current drugs and makes projections on drugs poised to influence the future market.
  
Diabetes is one of the most common diseases in the United States, affecting more than 24 million people. It is a metabolic disorder mainly caused by a defect in insulin production or absorption, resulting in a high level of blood glucose or blood sugar. A person having blood glucose level HbA1c of greater than seven ]]></description>
<pubDate>Sat, 14 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Spain Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12334.html</link>
<description> <![CDATA[Snapdata's Snapshots Spain Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Spanish pharmaceutical market and covers prescription and non-prescription (OTC) pharmaceuticals.  Market value and volume is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Spain Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots US Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12335.html</link>
<description> <![CDATA[Snapdata's Snapshots US Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US pharmaceutical market and covers Prescription and OTC Pharmaceuticals. Market value is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots US Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Venezuela Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12336.html</link>
<description> <![CDATA[Snapdata's Snapshots Venezuela Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Venezuelan pharmaceutical market and covers prescription medication and OTC pharmaceuticals. Market size is based on retail sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Venezuela Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Poland Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12332.html</link>
<description> <![CDATA[Snapdata's Snapshots Poland Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Polish pharmaceutical market and covers prescription pharmaceuticals and OTC pharmaceuticals. Market size is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Poland Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots South Africa Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12333.html</link>
<description> <![CDATA[Snapdata's Snapshots South Africa Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the South African pharmaceutical market and covers prescription and OTC drugs. Market Value is based on total domestic sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots South Africa Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Denmark OTC Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12329.html</link>
<description> <![CDATA[Snapdata's Snapshots Denmark OTC Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Danish OTC pharmaceutical market and covers the total consumption of OTC medicine in Denmark divided into therapeutic groups, measured in wholesale prices, Danish Kroner (DKK) 1,000. Market Value is based on consumption in wholesale prices. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Denmark OTC Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots US OTC Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12330.html</link>
<description> <![CDATA[Snapdata's Snapshots US OTC Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US OTC pharmaceutical market and covers non-prescription cough remedies, indigestion remedies, analgesics, vitamins, cold tablets/allergy/sinus, nasal remedies, ear drops/treatments and others. Market value is based on chemistsâ&#128;&trade; sales at manufacturersâ&#128;&trade; prices. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots US OTC Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots Hungary Pharmaceuticals 2009</title>
<link>http://www.mindbranch.com/products/R512-12331.html</link>
<description> <![CDATA[Snapdata's Snapshots Hungary Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Hungarian pharmaceutical market and covers prescription and OTC pharmaceuticals. Market value is based on sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Hungary Pharmaceuticals 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Snapshots US Nasal Products 2009</title>
<link>http://www.mindbranch.com/products/R512-12328.html</link>
<description> <![CDATA[Snapdata's Snapshots US Nasal Products 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US nasal product market and covers sprays, drops and inhalers, strips and nasal aspirators. Market value is based on grocery and pharmacy sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots US Nasal Products 2009 forms part of Snapdata's Pharmaceuticals industry ]]></description>
<pubDate>Thu, 12 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Global Digital Economy - E-Government, E-Health and E-Education Trends</title>
<link>http://www.mindbranch.com/products/R170-1258.html</link>
<description> <![CDATA[This annual report offers a wealth of information on the worldwide development of digital economy in terms of e-government, e-health and e-education. It offers analyses, statistics, forecasts and key trends. It provides insight into National Broadband Network (NBN) infrastructure developments and strategy. Regional information on developments in North America, Latin America, Europe, Middle East, Africa and Asia Pacific are also provided, where applicable. 
  Subjects covered include:  
 Key elements of the digital economy; 
 Global e-government overview and statistics; 
 Global e-health overview and statistics; 
 Global e-education overview; 
 Vision of the digital economy after the crisis; 
 Insight into National Broadband Network (NBN) developments; 
 Brief regional overviews on e-government, e-health and e-education developments where applicable. 
]]></description>
<pubDate>Wed, 11 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Nigeria Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8740.html</link>
<description> <![CDATA[The value of Nigeria&rsquo;s pharmaceutical market in 2008 was NGN80.9bn (US$680mn). We forecast a12.8% year-on-year (y-o-y) growth in local currency during 2009, expecting that the market will grow bya compound annual growth rate (CAGR) of 10.19% over our five-year forecast period (2009-2014), toreach NGN148.2bn (US$1.2bn). At the same time, expenditure on medicines as a percentage of GDP willcontinue to hover around a minor 0.3%, illustrative of the emerging status of the market and thewidespread lack of access to and financing for necessary medicines. In fact, Nigeria is viewed as thethird-least promising market in the Middle East and Africa (MEA) region, as ranked by BMI&rsquo;s Q110Pharmaceutical Business Environment Ratings (BER) that assess the 17 key countries.  Moreover, Nigeria continues to battle trade in counterfeit medicines. In August 2009, Nigerian authoritiesproposed a new strategy for the reduction of counterfeiting in the country. In addition to placing emphasison only allowing accredited and qualified personnel ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Kenya Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8739.html</link>
<description> <![CDATA[BMI&rsquo;s proprietary Drug Expenditure Forecast Model reveals that the Kenyan pharmaceutical market willreturn to a double-digit growth rate in 2009 (in local currency terms), after declining to single-digitgrowth the previous year. During 2008, OTC and prescription medicine sales reached KES17.7bn(US$0.229bn), up from KES14.4bn (US$0.215bn) in 2007. This represented a 9.6% growth in localcurrency terms and a 6.7% growth in US dollar terms, down from the 13.2% and 21.5% growth ratesachieved during 2007. By 2014, BMI believes that the Kenyan drug market will reach a value ofKES33.48bn (US$0.650bn), equating to a compound annual growth rate (CAGR) of 13.53% in localcurrency terms and 22.8% in US dollar terms. By 2019, BMI expects the pharmaceutical market to havereached a value of KES57.2bn (US$1.49bn), a 2009-2019 CAGR of 26.35% in Kenyan shilling terms anda staggering 45.0% in US dollar terms.  In BMI&rsquo;s Business Environment Ratings for Q110, despite Kenya&rsquo;s overall pharmaceutical ratingimproving marginally to reach ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Argentina Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8735.html</link>
<description> <![CDATA[The value of Argentina&rsquo;s pharmaceutical market in 2008 was US$3.7bn. BMI&rsquo;s updated forecasts see themarket reaching a value of US$6.12bn by 2014, representing a compound annual growth rate (CAGR) of12.68% in US dollar terms. With Argentina&rsquo;s economy bouncing back after the economic crisis at thebeginning of the decade, we expect the total value of the drug market to reach US$9.3bn by 2019.  However, the deep global recession has had a short-term impact on drug expenditure in Argentina, as outof-pocket spending and government finances were hit, and the Argentine peso was devalued. Indeed, in2009 we forecast that the drug sector will shrink by 10% in US dollar terms before recovering in 2010.  However, the long-term fundamentals of the market remain strong, and in BMI&rsquo;s opinion Argentina isone of the most promising pharmaceutical markets in Latin America in terms of growth prospects.  Despite the economic downturn, Argentina&rsquo;s government has promised to continue to invest heavily ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Merck &amp; Co. Performance, Products, Pipeline and Potential</title>
<link>http://www.mindbranch.com/products/R16-23326.html</link>
<description> <![CDATA[Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D.  An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Thailand Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8718.html</link>
<description> <![CDATA[In BMI&rsquo;s Pharmaceutical Environment Ratings (BER) table for Q110, Thailand slipped from ninth totenth position among the 15 key markets surveyed in the Asia Pacific region. Thailand&rsquo;s growing andageing population represents a substantial commercial opportunity for drugmakers, although itscontroversial compulsory licensing scheme is deterring foreign investment, as is its political instability.Additionally, the local operating environment is considered to be negative from the point of view offoreign research-based companies, due to a lack of data exclusivity, rife counterfeiting and parallelimportation, compounded by the introduction of health economics in the approval of patented drugs.  However, prospects for patent law reform are improving, as a result of Thailand&rsquo;s involvement in regionalharmonisation initiative and the resumption of talks with the US over a free trade agreement (FTA).  Nevertheless - and despite the currently low per capita spending on medicines - Thailand&rsquo;spharmaceutical market is expected to perform better than most of its regional peers, as global economicdownturn ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Australia Pharmaceuticals and Healthcare Report Q1 2010</title>
<link>http://www.mindbranch.com/products/R302-8717.html</link>
<description> <![CDATA[Australia&rsquo;s pharmaceutical market is among the most developed in the Asia-Pacific region. Access tomedication is good across all sections of the population, with per-capita spending calculated at US$352 in2008. While not particularly high by Western European or North American standards, it represents thesecond highest level in the region, behind only Japan. Over the next 10 years BMI forecasts that spendingon pharmaceuticals - including all prescription and over-the-counter (OTC) medicines - will increase at acompound annual growth rate (CAGR) of 3.1%, representing modest, if not overly impressiveperformance.  The Asia Pacific region&rsquo;s attractiveness to research-based multinational drugmakers has increased,according to BMI&rsquo;s Pharmaceuticals Business Environment Ratings for Q110. Australia has maintainedits premier ranking in the Business Environment Ratings for the Asia Pacific region in Q110. Australia&rsquo;sposition, ahead of the far higher value market of Japan, reflects more positive growth dynamics and morefavourable general market conditions.  Australia&rsquo;s population will expand steadily over the next decade, driven ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Company Financials: Bayer AG</title>
<link>http://www.mindbranch.com/products/R313-57885.html</link>
<description> <![CDATA[ Introduction   The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements.    Scope   Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation  Provides key ratios  Includes information on revenue distribution by business segments and geographies   Highlights   Bayer is a German chemical and pharmaceutical group. It operates in Asia Pacific, Europe, North America, Latin America, Africa, and Middle East.   Reasons to Purchase   Access important financial information and analysis on the company in a single datapack  Understand the financial evolution of the company over the last five years  Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization   Please note:   this is delivered as a Zip ]]></description>
<pubDate>Tue, 10 Nov 2009 00:00:00 EST</pubDate>
</item>
</channel>
</rss>
